Pharmaceutical

Tuberculosis cases nearly back to pre-pandemic levels, ...

Early in the Covid-19 pandemic, new diagnoses of tuberculosis dropped like a sto...

STAT+: Pharmalittle: FDA panel backs conditional approv...

A FDA advisory panel concluded that a Biogen treatment for a rare, genetic form ...

STAT+: Key senators blast Medicare Advantage insurers f...

Sens. Elizabeth Warren, Jeff Merkley are blasting Medicare Advantage insurers fo...

‘It’s a universal experience’: Doctor who treats Boston...

Physician Jim O'Connell says his nonprofit is "not solving homelessness, but car...

Former surgeon general Jerome Adams tries to outrun the...

Former surgeon general Jerome Adams has emerged as a leading voice on public hea...

STAT+: Drugmakers push back on a clever tactic employer...

Health plan sponsors are excluding pricey specialty drugs from coverage, then ta...

Pfizer acquires ADC pioneer Seagen for $43bn

Seagen generated almost $2bn in revenue in 2022, an increase approaching 25% fro...

Biotech’s post-IPO boom: rebounding from a 2022 Low?

In 2022, the biotech IPO market saw fewer offerings, and those that did manage t...

Biohaven licenses Hangzhou Highlightll’s BHV-8000 to tr...

Biohaven is expecting to advance Hangzhou Highlightll’s BHV-8000 into a Phase I ...

New medications for PCOS slowly edge toward development

While lifestyle modifications play a key role in treating PCOS, the paucity of n...

US FDA approves Incyte’s merkel cell carcinoma therapy

Incyte’s Zynyz is approved based on the data obtained from the POD1UM-201 trial.

Aseptic lyophilisation: Opportunities to improve qualit...

Mass spectrometry is one of the most versatile technologies you can integrate in...

MHRA revamps UK clinical trial regulation with the prom...

The MHRA introduces new changes to UK clinical trial regulation in hopes of reco...

Prometheus’ PRA023 could address an immediate need in C...

A clear issue currently facing gastroenterologists treating CD is the lack of in...

China’s NMPA grants EUA to CSPC Pharmaceutical’s Covid-...

CSPC Pharmaceutical’s SYS6006 has been designed to target some major Omicron var...

Digital health tech: a solution to substance use disord...

Healthcare providers are under pressure to address the growing issue of substanc...